ORTINGLOBE16.30

ORTIN GLOBAL LIMITED

· Pharma & Health
₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹13.3 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt1.80.31.01.0
Net Debt1.3-0.10.40.4
Total Debt/Equity0.640.130.810.81
Net Debt/Equity0.48-0.060.320.32
Total Debt/EBITDA-0.28-0.28-0.97-0.97
Net Debt/EBITDA-0.210.14-0.39-0.34
Interest Coverage (EBIT/Interest)-14.04-331.59-470.77-470.77
Total Debt/Total Capital %38.9611.2244.8244.82
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.